Form 4 for ALKS Alkermes plc.
Accepted 2024-02-12 00:00:00 ET · period of report 2024-02-08 · accession 0001127602-24-004630 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-12 | 2024-02-08 | ALKS | Hopkinson Craig C. | EVP R, D, Chief Medical Off | A - Grant | — | +46.7K | 103.2K | +82% | — |
| D | 2024-02-12 | 2024-02-08 | ALKS | Hopkinson Craig C. | EVP R, D, Chief Medical Off | F - Tax | $26.77 | -15.3K | 87.9K | -15% | -$409.0K |
| DM | 2024-02-12 | 2023-11-17 | ALKS | Hopkinson Craig C. | EVP R, D, Chief Medical Off | J - Other | $29.44 | +19.1K | 108.8K | +21% | +$563.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-02-08 | A | A | 46,658 | — | 103,217 | D | — | — | (F1) These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 22, 2021 with a three-year performance period that ended on December 31, 2023 (the "2021 PRSUs"). The vesting of this portion of the 2021 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2021 PRSUs. |
| 2 | Common | Ordinary Shares | 2024-02-08 | F | D | 15,280 | $26.77 | 87,937 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit Award | 2023-11-17 | J | A | 523 | — | 26,690 | D | — · — to — | 523 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F5) Each restricted stock unit represents a contingent right to receive one ordinary share. (F10) Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. |
| 4 | Derivative | Employee Stock Option (Right to Buy) | 2023-11-17 | J | A | 2,412 | $26.82 | 123,027 | D | $26.82 · — to 2033-02-23 | 2,412 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F11) Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024. |
| 5 | Derivative | Restricted Stock Unit Award | 2023-11-17 | J | A | 603 | — | 30,757 | D | — · — to — | 603 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F5) Each restricted stock unit represents a contingent right to receive one ordinary share. (F12) Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024. |
| 6 | Derivative | Employee Stock Option (Right to Buy) | 2023-11-17 | J | A | 1,599 | $58.40 | 81,599 | D | $58.40 · — to 2027-06-07 | 1,599 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F3) These options are fully vested in accordance with their terms. |
| 7 | Derivative | Employee Stock Option (Right to Buy) | 2023-11-17 | J | A | 1,089 | $65.94 | 55,589 | D | $65.94 · — to 2028-02-16 | 1,089 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F3) These options are fully vested in accordance with their terms. |
| 8 | Derivative | Employee Stock Option (Right to Buy) | 2023-11-17 | J | A | 2,790 | $24.59 | 142,344 | D | $24.59 · — to 2032-02-18 | 2,790 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F9) Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023. |
| 9 | Derivative | Employee Stock Option (Right to Buy) | 2023-11-17 | J | A | 3,376 | $20.03 | 172,232 | D | $20.03 · — to 2030-02-20 | 3,376 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F4) Shares subject to the stock option award vest and become exercisable in four equal annual installments commencing on 2/20/2021. |
| 10 | Derivative | Restricted Stock Unit Award | 2023-11-17 | J | A | 201 | — | 10,297 | D | — · — to — | 201 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F5) Each restricted stock unit represents a contingent right to receive one ordinary share. (F6) Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021. |
| 11 | Derivative | Employee Stock Option (Right to Buy) | 2023-11-17 | J | A | 3,929 | $19.34 | 200,413 | D | $19.34 · — to 2031-02-22 | 3,929 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F7) Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022. |
| 12 | Derivative | Restricted Stock Unit Award | 2023-11-17 | J | A | 481 | — | 24,557 | D | — · — to — | 481 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F5) Each restricted stock unit represents a contingent right to receive one ordinary share. (F8) Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022. |
| 13 | Derivative | Employee Stock Option (Right to Buy) | 2023-11-17 | J | A | 2,133 | $31.93 | 108,833 | D | $31.93 · — to 2029-02-21 | 2,133 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F3) These options are fully vested in accordance with their terms. |